Comparison · NCT03091192-sae
Savolitinib QD vs Sunitinib QD: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Savolitinib QD vs Sunitinib QD: serious adverse events. Trial comparisons, record NCT03091192-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03091192-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.242 | 0.128 | 0.41 | wilson | |
| Risk in group 2 | 0.296 | 0.159 | 0.485 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0539 | -0.274 | 0.163 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.818 | 0.354 | 1.89 | log | |
| Odds ratio, group 1 over group 2 | 0.76 | 0.241 | 2.39 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Savolitinib QD than on Sunitinib QD | 18.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Savolitinib QD | Savolitinib QD | 8 | 33 | EG000 |
| Group 2 | Sunitinib QD | Sunitinib QD | 8 | 27 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse Events (AEs) and Serious Adverse Events (SAEs) were collected throughout the study, from date of informed consent until 30 days after the last dose of study treatment.
Source ClinicalTrials.gov
Trial
- Title
- Savolitinib vs. Sunitinib in MET-driven PRCC.
- NCT number
- NCT03091192
- Phases
- PHASE3
- Conditions
- Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors
- Interventions
- Savolitinib, Sunitinib
- Lead sponsor
- AstraZeneca
- Results first posted
- 2020-07-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03091192?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03091192-sae